M E Pavel
Affiliation: University of Erlangen-Nuremberg
- Impact of growth hormone on central nervous activity, vigilance, and tiredness after short-term therapy in growth hormone-deficient adultsM E Pavel
Division of Endocrinology, Department of Internal Medicine I, University of Erlangen Nurnberg, Germany
Horm Metab Res 35:114-9. 2003..Although results must be interpreted cautiously due to the small sample size, we conclude that the improved sleep and mood parameters might be caused by other indices of general well-being in our study...
- Long-term follow-up of childhood-onset hypopituitarism in patients with the PROP-1 gene mutationMarianne E Pavel
Division of Endocrinology, Department of Internal Medicine I, University Erlangen Nurnberg, Germany
Horm Res 60:168-73. 2003..The PROP-1 gene mutation is a rare disorder leading to combined pituitary hormone deficiencies over time. The aim was to analyze the clinical picture of 40 years of an almost untreated PROP-1 gene mutation...
- Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumorsMarianne E Pavel
Department of Medicine I, University of Erlangen Nuremberg, Ulmenweg 18, 91054 Erlangen, Germany
Int J Gastrointest Cancer 35:179-85. 2005..It is not clear what therapy should be applied after failed biotherapy. Our aim was to establish whether patients whose tumors rapidly progress under biotherapy may benefit from chemotherapy...
- Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomasMarianne E Pavel
Department of Medicine I, University Hospital Erlangen Nuremberg, 91054 Erlangen, Germany
J Interferon Cytokine Res 26:8-13. 2006..Better tolerability of PEG-IFN-alpha2b improved patients' compliance, justifying its use in patients who do not tolerate conventional IFN-alpha treatment...
- Adrenomedullin is a novel marker of tumor progression in neuroendocrine carcinomasM E Pavel
Division of Endocrinology, Department of Medicine I, Erlangen Nürnberg University Hospital, Germany
Horm Metab Res 38:112-8. 2006..Adrenomedullin might represent a useful prognostic marker in patients with neuroendocrine carcinomas...
- Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomasMarianne E Pavel
Department of Medicine I, University Hospital Erlangen Nuernberg, Ulmensweg 18, 91054 Erlangen, Germany
Clin Endocrinol (Oxf) 62:434-43. 2005..The aim of our study was to investigate whether tumour growth could be correlated with the release of proangiogenic factors into the circulation...
- Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic)Ola Nilsson
Department of Pathology, Gothenburg University, Gothenburg, Sweden
Neuroendocrinology 84:212-5. 2006
- Poorly-differentiated endocrine carcinomas of midgut and hindgut originHakan Ahlman
Department of Surgery, Sahlgrenska University Hospital, Goteborg, Sweden
Neuroendocrinology 87:40-6. 2008